ERAS-0015 Pancreatic Cancer Pill Shrinks Tumours in 44% of Pretreated Patients
Erasca's oral pan-RAS molecular glue ERAS-0015 produced a 44% confirmed response rate in pretreated KRAS-mutant pancreatic cancer, 69% in G12D/G12V tumours, in Phase 1.
Erasca's oral pan-RAS molecular glue ERAS-0015 produced a 44% confirmed response rate in pretreated KRAS-mutant pancreatic cancer, 69% in G12D/G12V tumours, in Phase 1.